Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Releases

429 Press Releases
DateTitleCompany
21 Nov 16 Teva Secures European Approval of Trisenox® for First Line Treatment of Low to Intermediate Risk Acute Promyelocytic Leukemia (APL) Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
08 Nov 16 Teva Announces Appointment of New Chief Legal Officer Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
07 Nov 16 Teva Announces Approval of Generic Tribenzor® in the United States Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
02 Nov 16 CMS Establishes Unique J-Code for BENDEKA® (Bendamustine Hydrochloride) Injection Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
31 Oct 16 Teva to Report Third Quarter 2016 Financial Results on November 15, 2016 Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
26 Oct 16 Teva Pharmaceuticals and IBM Expand Global Partnership to Enable Drug Development and Chronic Disease Management with Watson Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
20 Oct 16 Teva Announces FDA Acceptance of Resubmitted New Drug Application for SD-809 for Treatment of Chorea Associated with Huntington Disease Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
17 Oct 16 Teva Receives Positive Opinion from European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) to Extend Indication of Trisenox® for First Line Treatment of Low- to Intermediate Risk Acute Promyelocytic Leukemia (APL) Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
12 Oct 16 Teva Announces Launch of Generic Beyaz® in the United States Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
06 Oct 16 Teva and Celltrion Announce Exclusive Biosimilar Commercial Partnership Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
05 Oct 16 Teva Announces Sale of UK and Ireland Actavis Assets and Operations Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
03 Oct 16 Teva Completes Acquisition of Anda, Inc. Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
28 Sep 16 Teva Announces Launch of Generic Epzicom® Tablets in the United States Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
22 Sep 16 Teva Announces Positive Top-Line Data from Second Phase III Study of SD-809 in Tardive Dyskinesia (TD) Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
19 Sep 16 Teva Announces Results from Exploratory 52-Week Phase 2 PRIDE-HD Study of Pridopidine in Huntington Disease Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
15 Sep 16 Teva Strengthens Injectables Portfolio with the Launch of an Authorized Generic of Cubicin® (Daptomycin for Injection) in the United States Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
15 Sep 16 Teva to Develop Unique Wearable Tech and Machine Learning Platform for Continuous Measurement & Analysis of Huntington Disease Symptoms in Collaboration with Intel Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
30 Aug 16 Teva to Present New Respiratory Data at the 2016 European Respiratory Society (ERS) International Congress Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
12 Jul 16 Teva to Host Conference Call and Webcast to Provide Preliminary Outlook for 2016-2019 Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
18 Aug 16 European Commission Grants Marketing Authorization for Teva’s CINQAERO® (reslizumab) Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
27 Jul 16 Teva Receives Clearance from the U.S. Federal Trade Commission for Actavis Generics Acquisition Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
20 Jul 16 Teva Announces Pricing of Additional €4.0 Billion of Senior Notes in Connection with Pending Acquisition of Actavis Generics Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
28 Jun 16 Teva Announces FDA Acceptance of New Drug Applications for Fluticasone Propionate/Salmeterol and Fluticasone Propionate RespiClick® Inhalers Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
05 Aug 16 Teva Announces Launch of Generic Gleevec® Tablets in the United States Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
27 Jul 16 Teva to Report Second Quarter 2016 Financial Results on August 4, 2016 Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
24 Aug 16 Teva Confirms PTAB’s Decisions on Two Patents in IPR Challenge to COPAXONE® 40 mg Kevin C. Mannix Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
02 Aug 16 Teva Completes Acquisition of Actavis Generics Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
03 Aug 16 Teva Announces Acquisition of Anda Inc. Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
19 Jul 16 Teva Announces Pricing of $15 Billion of Senior Notes in Connection with Pending Acquisition of Actavis Generics Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
05 Jul 16 Teva and the Huntington Study Group Announce Publication of Pivotal Phase III Data on Deutetrabenazine (SD-809) in Huntington Disease from First-HD Trial in JAMA Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.